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Abstract  
 
Th17 cells have non-redundant roles in maintaining immunity, particularly at mucosal 
surfaces. These roles are achieved principally through the production of cytokines and the 
recruitment of other immune cells to maintain the integrity of mucosal barriers and prevent 
the dissemination of microorganisms. Th17 cells are heterogeneous and exhibit a considerable 
degree of plasticity. This allows these cells to respond to changing environmental challenges. 
In addition to their protective role in immunity, studies involving animal models, patient data, 
genome wide association studies and clinical trials targeting IL-17 for treatment of patients 
have provided evidence that Th17 cells also play pro-inflammatory roles in chronic 
autoimmune diseases. Less clear, however, are triggers that initiate or perpetuate Th17 
responses to promote chronic inflammation and autoimmunity, and the divergent effects of 
tumour necrosis factor alpha blockade on Th17 cells in patient subgroups. Th17 cells also 
stimulate B lymphocytes and enhance humoral immunity by inducing polyclonal activation of 
autoreactive B lymphocytes, leading to autoantibody production. In addition, some 
pathogenic bacterial species can change Th17 cell phenotype and responses. These effects are 
implicated in promoting pathogenic roles for Th17 cells in autoimmune diseases. This article 
provides an overview of the distinct roles Th17 cells can play in maintaining immunity at 
mucosal surfaces and in skin mucosa and how this is linked to chronic inflammation in 
autoimmune rheumatic diseases.  
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Introduction 
 
Th17 cells are effector T cells characterised primarily by the production of IL-17, principally 
IL-17A and IL-17F but also IL-22, IL-21 and GM-CSF.
1
 The cells play an important role in 
maintaining immunity, particularly at mucosal surfaces but also contribute to chronic 
inflammation in autoimmune diseases.
1-3
 Although many studies have explored the role of 
Th17 cells in the pathogenesis of autoimmune diseases using animal models, clinical samples 
from patients, clinical trials targeting IL-17 therapeutically and genome wide association 
studies (GWAS), there is still a lack of understanding of how Th17 cells are transformed from 
non-pathogenic protective lymphocytes to a major mediator of chronic and sometimes fatal 
inflammation. Evidence from studies of animal models and clinical trials suggest that TNFα is 
a suppressor of pro-inflammatory activities mediated by Th17 cells.
4-6
 In this review, we 
provide an overview of current knowledge of the functional heterogeneity and phenotypic 
plasticity of Th17 cells. We will highlight factors thought to drive the protective functions 
versus pathogenic roles of Th17 cells in autoimmunity, with an emphasis on rheumatic 
diseases. 
 
Differentiation of Th17 cells 
 
Th17 differentiation and function in health: the gut and skin  
 
In healthy humans, most Th17 cells are found in the intestinal lamina propria with some also 
being part of the cutaneous antigen positive resident memory T cell population (TRM) in the 
skin (Figure 1).
7,8
 Steady-state Th17 cell differentiation is dependent on IL-1β, IL-6, IL-23 
and TGFβ.
1
 Low levels of IL-1β from macrophages, induced by intestinal commensal 
bacteria, maintains Th17 protective functions.9 TGFβ, produced during the turnover of 
epithelial cells, is also abundant in the gut mucosa.
10
 Furthermore, exogenous tryptophan and 
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other metabolites activate the transcription factor aryl hydrocarbon receptor (AhR) and 
augment Th17 cell differentiation.
1
 Sodium chloride and hypoxia can also influence Th17 
cells, with the former promoting Th17 differentiation whilst the latter modulates IL-17 
production.
1 
In the skin, the commensal bacterial species Staphylococcus epidermidis induces 
IL-1α and IL-1β production, which favour Th17 differentiation.
8 
 
In the intestine, Th17 cells produce IL-22 and IL-17. These two cytokines protect mucosal 
membranes by inducing the production of antimicrobial proteins, RegIIIβ and RegIIIγ.
11
 They 
also help maintain tight epithelial cell junctions and promote epithelial cell re-generation.
1,12
 
Th17 cells play comparable roles in the skin and in the airways of the lung.
13
 The importance 
of Th17 cells in maintaining anti-microbial immunity is underscored by the fact that patients 
with loss-of-function mutations in genes coding for IL-17, IL-17 receptor or RORγt 
experience recurrent infections (e.g. Candida albicans and Staphylococcus aureus) of the 




The IL-17 receptor is expressed on several cell types including epithelial and endothelial 
cells, fibroblasts, keratinocytes and monocytes.
1
 IL-17 binding to its receptor triggers the 
production of chemokines CXCL1, 5, 8, 9 and 10, CCL2 and 20 and cytokines such as IL-
6.
1,15
 The chemokines attract neutrophils, T cells and NK cells which, in response to IL-17, 
produce IFNγ and GM-CSF leading to more neutrophil influx to eradicate fungi (Figure 1).
16
 
CCL20, by binding CCR6, which is highly expressed by Th17 cells, recruits more cells to 
sites of infection.
15
 IL-17 signalling also leads to β-defensin and S100 production that act on 
invading micro-organisms (Figure 1).
1
 In addition, IL-17 induces the production of matrix 
metalloproteinases (MMPs) which facilitate the cleavage and activation of anti-microbial 
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Th17-derived IL-21 promotes humoral immunity by activating follicular T helper cells (Tfh) 
and B cells. By promoting B cell proliferation, antibody affinity maturation, class switching 
and differentiation to plasma cells, Tfh cells promote humoral immunity in secondary 
lymphoid organs and germinal centres.
1,19,20
 Studies of gut inflammation and vaccine 





A possible clue as to how protective Th17 responses can “spill-over” into inflammation has 
been provided by studies of a mouse model of intestinal infection in which commensal 
segmented filamentous bacteria (SFB) induced an inflammatory Th17 cell response in the 
gut.
3
 SFB and Citrobacter rodentium are more effective at inducing intestinal Th17 responses 
than other microbial species due to their ability to penetrate the protective mucus and adhere 





Intracellular signalling and Th17 differentiation 
T cell receptor (TCR) engagement in the presence of IL-1β activates nuclear factor kappa B 
(NF- B) and interferon regulatory factor 4 (IRF4).23 Together with the basic leucine zipper 
transcription factor, ATF-like (BATF), NF- B and IRF4 translocate to the nucleus to 
reorganize chromatin sites relevant to Th17 cell differentiation.
23
 Exposure to IL-6 and IL-23 
phosphorylates signal transducer and activator of transcription 3 (STAT3) and causes it to 
dissociate from the receptor-bound Janus kinase 2 (JAK2).
24
 STAT3 in Th17 cells can be 
phosphorylated on the amino acids tyrosine 705 and serine 727.
25
 Phosphorylated STAT3 
(pSTAT3) translocates to the nucleus to populate permissive chromatin sites, made accessible 
by TGFβ, to stabilize BATF/IRF4 interactions.
1
 The IRF4/BATF/STAT3 interaction induces 
the expression of Th17-associated genes such as Il17a, Il17f, IL23r, Ccr6, Rorα and Hif1a.
23
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Genes coding for IL-17A and IL-17F are located in close proximity to each other on human 
chromosome 6 (murine chromosome 1) and are co-regulated. In mice, IL-23 induces runt-
related transcription factor 1 (RUNX1) gene expression to enhance expression of ROR t, an 
important cell lineage-specific transcription factor which, together with pSTAT3, binds 
promoters for Il17a and other Th17-related genes.
23
 The transcription factor, Blimp-1, 




Super-enhancers are important regulatory elements characterized by a high density of both 
non-specific and lineage-specific transcription factors in multiple enhancer elements found in 
untranscribed chromatin. In cells destined to become Th17 cells, these regulatory elements are 
themselves regulated by multiple factors, including cytokines, TCR-engagement and 
environmental factors. STAT3 and RORγt are co-localized in such regions in the 
neighbourhood of genes involved in Th17 cell regulation and effector functions. These genes 




Heterogeneity and stability of Th17 cells 
High-dimensional phenotyping by mass-cytometry (CyToF) has shown that human Th17 cells 
have a heterogeneous phenotype.
7
 This concept is supported by single-cell RNA-sequencing 
(RNAseq) of murine Th17 cells which revealed considerable heterogeneity due to the existence 
of distinct Th17 cell subsets and different maturational states.
28
 Immature Th17 cells have a 
stem cell-like gene-signature and are generally confined to lymph nodes. A more mature Th17 
cell subset was identified as having high Stat3 and Rankl mRNA levels while a further subset 
was shown to mainly produce IFNγ.
28
 Hence, although Th17 cells are categorised by IL-17 
production and by their presence in the skin, colon, lungs and tonsils, some Th17 cells also 
produce IL-10, IL-22 and IFNγ.
7
 Furthermore, different pathogens induce different cytokine 
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responses in Th17 cells (Figure 1). For example, Th17 cells induced by C. albicans tend to 




Exposure to pathogens in the presence of different cytokines alters the transcriptional profile of 
Th17 cells. For example, IL-23 induces RUNX1 expression that promotes Th17 differentiation 
while IL-12 induces T-bet expression with a Th1-like cells that produce IFNγ.
30
 In 
experimental autoimmune encephalomyelitis in mice and in patients with multiple sclerosis, 




Further studies have shown that murine Th17 cells in the gut mucosa can transdifferentiate to 
IL-10-producing regulatory T cells (Tr-1 cells), a process apparently dependent on the AhR and 
TGFβ (Figure 1).
1
 The ability of Th17 cells to produce IL-10 is also noted following treatment 
with TNFα inhibitors.
33
 The production of IL-10 by Th17 cells is regulated by the transcription 
factors c-Maf and Aiolos.
1,33
 Early studies, however, suggested that Th17 cells and Tregs were 
mutually exclusive. These studies indicated that Th17 cell development was inhibited by IL-2 
and STAT5 activation. Recent studies, however, have shown that Th17 cells can 




In mice, Th17 cells in Peyer’s patches can transdifferentiate to Tfh cells and facilitate IgA 
production by B cells.
21
 In contrast, in an inflammatory milieu containing IL-23, Blimp-1 is 
induced and this, in turn, promotes the emergence of a pathogenic Th17 phenotype in which 




Th17 cells as drivers of autoimmunity 
Autoimmune diseases are often associated with autoreactive T cell oligoclonality and the 
recognition of disease-related auto-antigens (Table 2).
37,38
 Small numbers of autoreactive T 
cells can also be detected in healthy individuals but these are generally anergic and do not 
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promote chronic inflammation and disease.
39
 Changes in the balance between Tregs and Th17 
cells have been implicated in shifting the balance between limiting and sustained 
autoimmunity.
40
 Studies in animal models and in patients have indicated that the plasticity of 
Th17 cells contributes to disease in a permissive inflammatory milieu.
2,31,41
 For example, IL-
23-mediated inflammation in EAE mice induced Th17 cells to produce IFNγ.
31
 Further, a 
study of peripheral blood cells from SLE patients revealed a subgroup of patients with a 
proportion of their Th17 cells likely transdifferentiated to Tregs.
41
 Several genes identified by 
GWAS to be associated with TCR and cytokine signalling influence the activity and plasticity 
of Th17 cells. Furthermore, various SNPs associated with changes in gene expression levels 
or disruption of TCR and cytokine signalling proteins have been directly implicated in Th17 
cell functions (summarised in Table 1). 
 
Th17 cells have lower activation thresholds than Th1 cells and are, therefore, more prone to 
become self-reactive effector cells.
2,42
 Indeed, environmental pollutants and bacteria that are 
better at penetrating the mucosa and persist in the gut can promote self-reactive Th17 
responses.
22,43
 Furthermore, a study of an animal model of intestinal infection has shown that 
a milieu containing IL-23 and apoptotic epithelial cells preferentially promoted self-reactive 




Many autoimmune diseases are associated with the production of autoantibodies and several 
studies have identified links between Th17 cells, B cell activation and autoantibody 
production (Table 2). For example, the B cell activating factor (BAFF), which is important for 
B cell activation, also augments Th17 differentiation by facilitating upregulation of the IL-6 
receptor on CD4
+
 T cells, suggesting that the proliferation of the two cell types could occur 
concurrently.
44 
Furthermore, experimental SFB infection promotes Th17 cell differentiation, 
germinal centre formation, autoantibody production and autoimmune disease.
3,45,46
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Th17 cells and rheumatoid arthritis (RA) pathogenesis 
RA is a debilitating disease affecting 0.5-1% of the population worldwide. The synovial 
lining of RA joints is targeted by an immune response that induces juxta-articular bone loss.
47
 
T cells in the synovium of RA patients manifest a relatively restricted, or oligoclonal, receptor 
(TCR) repertoire. The cause of this restricted repertoire is suggested to be the exhaustion and 





High blood levels of IL-17 are evident in patients with RA several years before the 
development of clinical disease.
48
 Furthermore, Th17 cells are enriched in arthritic joints
49
 
and these cells can promote arthritis by inducing the production of pro-inflammatory 
cytokines while inhibiting apoptosis in synoviocytes.
50
 In addition, IL-17 induces MMP-1 and 
MMP-3 production from synovial fibroblasts, leading to collagen degradation.
51
 Th17 cells 




Studies in animal models of arthritis have indicated that self-reactive T cells differentiate to 
Th17 cells due to the inflammatory synovial milieu.
53
 However, in RA no single self-antigen 
target for T cells has been identified. A number of GWAS have identified genetic associations 
between susceptibility to RA and chemokine receptors, cytokines- and TCR signalling (Table 
1).
47
 These findings imply that the risk for developing RA is increased by the combined 
effects of RA-permissive HLA alleles and dysregulated inflammatory signalling pathways, in 
which Th17-associated genes are over-expressed. 
 
Other studies of Th17 cells in RA have suggested the existence of a reciprocal relationship 
between Tregs and Th17 cells. For example, the ratio of Th17 to Treg cells is significantly 
greater in RA patients compared with healthy individuals.
40
 Moreover, the Th17:Treg ratio 
decreases in response to treatment with the anti-IL6 receptor antibody Tocilizumab.
54
 Such a 
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relationship has been suggested to be primarily due to the plasticity of Th17 cells and studies 
in mice have confirmed that Tregs can transdifferentiate to Th17 cells in arthritic joints.
35
 In 




 T cells can be identified in RA synovia and this provides 
further evidence of Treg/Th17 transdifferentiation.
35
 Although some clinical trials has not 
shown efficacy when using anti-IL-17 therapy for RA, there is evidence for increased Th17 
cells following anti-TNFα therapy.
4,55,56
 Moreover, evidence from phase two clinical trials 
with methotrexate, or in anti-TNFα non-responsive patients indicate that disease in some RA 
patients is driven by Th17 cells and that treatment with anti-IL-17 antibody could be 




RA is traditionally associated with the presence of rheumatoid factors (RFs) and anti-cyclic 
citrullinated peptide (anti-CCP) auto-antibodies.
47
 Interestingly, Th17 cells have been 
identified in germinal centres of ectopic lymphoid structures (ELS) in joints of RA patients.
58
 
In mice, Th17 cells induce ELS in joints while germinal centre-resident Th17 cells reduce 
sialylation of IgG, thus, promoting pathogenic auto-antibody production.
46
 Relevant to the 
link between Th17 cells and autoantibody production is that BAFF activates both plasma cells 




Given the potential of Th17 cells to modulate B cell responses, it is of potential significance 
that anti-TNFα non-responder patients tend to produce anti-nucleic acid antibodies
60
 and that 
anti-TNFα therapy may interfere with cellular clearance mechanisms leading to lupus-like 
symptoms.
61
 Future research will determine whether such responses are driven by Th17 cells 
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Th17 cells and the pathogenesis of Psoriasis 
Psoriasis is manifested by uncontrolled proliferation of dermal keratinocytes. The disease 
affects 2-3% of populations worldwide, with a similar prevalence in both genders. The most 
common form of the disease is psoriasis vulgaris, in which the disease causes the appearance of 
itchy, red and scaly plaques all over the body.
62
 Psoriatic lesions are reduced by anti-
inflammatory therapy but often reoccur at the same location. Immune system involvement is 
indicated by association with HL-A class I haplotypes and by the therapeutic response of 
patients to immunosuppressive agents.
62
 GWAS have identified several candidate genes that 
provide evidence for an association between Th17 cells and susceptibility to the disease (Table 
1). 
 
Pathogenic T cells in psoriasis are not commonly detected in blood but reside in the skin.
63
 
Blockade of E-selectin prevents the egress of leukocytes from the circulation into the dermal 
tissue compartment but this does not improve disease.
64
 The importance of skin-resident T cells 
for psoriasis pathology is indicated by studies showing that engraftment of patient’s skin into 
immune deficient mice leads to a reaction to keratinocyte-derived proteins. Autoreactive T cells 
present in the graft were found to be responsible for the response (Figure 2).
65
 Such 
autoreactive T cells in psoriatic skin lesions are generally oligoclonal, produce IL-17 and IL-22 




The role of Th17 cell in psoriasis was initially suggested by studies in animal models. For 
example, mice deficient in IL-17 did not develop experimental psoriasis
66
 and administration of 
IL-23 or IL-21 into mouse skin induced psoriasis-like symptoms.
66,67
 The role of Th17 cells in 
psoriatic patients was thereafter verified by the effective therapeutic effect of human IgG1κ 
monoclonal antibodies targeting IL-17A and IL-17RA (Table 2).
68
 As cited earlier, at least in 
mice, some tissue resident T cells recognize C. albicans and respond by producing IL-17.
8
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Although C. albicans can exacerbate psoriasis via activation of T cells there is currently no 
evidence that the fungus is responsible for the pathogenic Th17 response.
69
 Instead, various 
keratinocyte proteins, such as ezrin, maspin, peroxiredoxin 2, heat shock protein 27 and LL-37 




The available evidence indicates that the activity of pathogenic Th17 cells is augmented 
indirectly by plasmacytoid dendritic cells (pDCs). pDCs produce type 1 interferons and TNFα 
that activate myeloid DCs (mDCs).
62
 mDCs, in turn, produce IL-23 and present self-antigens to 
activate tissue-resident Th17 cells. In this respect, there is evidence that blood IL-21 levels are 
increased in psoriasis and correlate with Psoriasis Area and Severity Index (PASI) scores.
62
 In 
addition, IL-21 is found in plaques of a murine model of psoriasis and is both produced by and 
augments Th17 cell activity in psoriatic patients.
72 
IL-17 produced in the plaques activates 
keratinocytes to produce IL-8, CCL-1, -3, -5, and -6, and 20. These chemokines help recruit 
neutrophils.
62
 CCL20 recruits further Th17 cells and DCs. IL-17 also increases the production 
of β-defensin and VEGF by fibroblasts which leads to angiogenesis and plaque formation.
17,73
 




Th17 cells in the pathogenesis of and autoantibody production in systemic lupus 
erythematosus (SLE) 
SLE affects 20-70 individuals per 100,000 of the population in the UK and has a 9:1 
female:male ratio.
74
 The aetiopathogenesis of SLE is thought to be driven by a combination of 
environmental and genetic factors. A key feature of SLE is defective removal of apoptotic 
bodies leading to the accumulation of cell debris of nuclear, cytosolic and membrane origin. 
This debris activates autoreactive B cells to proliferate and stimulate autoreactive T cells 
leading to the production of anti-nuclear autoantibodies.
74
 Although association of SLE with 
HLA is not as strong as in RA, a number of other immune-related gene candidates have been 
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linked to SLE. Several of these genes are involved in Th17 cell regulation (Table 1).
75
 Reduced 
global DNA methylation is also a feature of SLE.
76
 In this context, it may be relevant that 
reduced levels of the transcription factor, regulatory factor X1 (RFX1), was recently shown to 
result in reduced histone and DNA methylation. This leads to an increase in Th17 cell 




Effector Th17 cells found in the blood and tissues of patients with SLE are implicated in the 
pathogenesis of the disease.
36
 Imbalance in the intestinal microbiome, characterized by reduced 
Firmicutes:Bacteroidetes ratios, has been reported in SLE and shown to promote Th17 cell 
differentiation (Table 2).
36





 T cells suggestive of trans-differentiation (Figure 2).
36
 
Interestingly, the frequency of Th17 cells in SLE correlates with autoantibody levels, disease 
activity and high blood levels of IL-17.
36
 There is also evidence for increased Th17 cells co-
expressing IL-17 and IFNγ.
78
  Further evidence for a relationship between Th17 cells and lupus 
is provided by the therapeutic benefit of targeting of Th17 cells. Thus, a patient with psoriasis 




Interestingly, there is evidence for an association between defective TNFα signalling and SLE 
disease pathogenesis. This has been demonstrated in several contexts in animal models. For 
example, lupus mice deficient in TNFα receptors have higher numbers of Th17 cells and show 
accelerated pathology.
6
 This is consistent with the observation cited earlier in this review that 
blockade of TNFα in human patients leads to an increase in the frequency of Th17 cells and 
high levels of IL-17 production by T cells. Thus, there is an increase in the frequency of Th17 
cells in RA and psoriatic patients treated with biologic anti-TNFα agents.
4,5
 It not entirely clear 
how deficient TNFα signalling promote lupus pathology in mice. However, it is interesting to 
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note that TNFα-induced, ubiquitin editing enzyme A20/TNFAIP3 that acts downstream of 
TNFR1 has been linked in GWAS to RA, psoriasis and lupus (Table 1). In human patients with 
lupus, however, there is no experimental evidence that TNFα blockade exacerbates lupus 
because such patients are not routinely treated with biologic anti-TNFα agents. Indeed, any 
relationship between enhanced Th17 cell responses in SLE within the context of TNFα could 
be mediated through reduced expression TNFAIP3 in T cells. This reduced expression of 




Except for some circumstantial evidence for genetic associations from GWAS and reported 
changes in the gut microbiome, it remains unclear what is driving the generation of pathogenic 
Th17 cells in SLE. However, the inflammatory milieu in lupus underpins defective 
phagocytosis which, in turn, promotes IL-23 production leading to Th17 cell differentiation.
82
 
In addition, there are suggestions for a link between B cell differentiation and Th17 cell 
development. Thus, the transcription factor Blimp-1, which is encoded by the PRDM1 gene, 
another gene identified by GWAS to be associated with lupus, plays a role in the differentiation 
of Th17 cells and B cells to plasma cells (Table 1). Thus, Blimp-1 regulates differentiation of B 
cells to plasma cells but is also involved in the development of murine Th17 cells in response 
to IL-23. In Th17 cells, Blimp-1 represses transcription of Bcl6.
26
 As Bcl6 is required for Tfh 
differentiation, and SLE is associated with autoantibody production, one of the effects of 
disease associated PRDM1 polymorphisms could be the augmentation of Th17 cell-driven 




In addition to playing a role in autoantibody production in lupus, the Th17 axis has been 
implicated in accelerating organ damage and mortality.
83
 IL-23 levels are increased in the 
blood and urine of SLE patients compared with healthy controls. In addition, urine levels of IL-
23 correlate with renal SLE Disease Activity Index (rSLEDAI) score and with proteinuria. 
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After 6 months of treatment with immunosuppressive agents, a cohort of SLE patients showed 
a high frequency of CD4
+






T cells that produced 
IL-17.
78
 Interestingly, the T cells homed to the kidneys, produced copious amounts of IL-17 
and IFNγ and recruited neutrophils. These findings suggest that Th17 cells could contribute to 
lupus nephritis through the recruitment of neutrophils. Other studies, however, have focused on 
the link between Th17 cells and B cells. For example, lack of IL-17RA was shown to reduce 
while administration of IL-17 accelerated germinal centre formation in mice and enhanced 
autoantibody production.
45
 This role was supported by increased BAFF production.
84
 In this 
respect, and cited earlier, it is noteworthy that a lack of response to anti-TNFα in RA is 





Do Th17 cells contribute to the pathogenesis of systemic sclerosis (SSc)? 
SSc is an autoimmune connective tissue disease in which activation of the immune system, 
inflammation, vasculopathy and uncontrolled fibrosis lead to organ-based complications. The 
disease is exemplified by progressive dermal fibrosis and vasculopathy. SSc affects 12,000 
individuals in the UK with a female:male ratio of 9:1.
85
 Its aetiopathogenesis involves genetic 
and environmental factors, such as exposure to organic solvents and silica.
85
 The pattern of 
fibrotic disease is clinically classified as either limited or diffuse based on the extent of 
cutaneous involvement. The diffuse subtype, in particular, has an inflammatory phenotype with 
progressive fibrosis of lungs, kidneys, heart and the gastrointestinal tract in the first few years 
of disease onset.
85
 SSc is characterized by damage to the micro- and macro-vasculature leading 
to tissue hypoxia with excessive accumulation of extracellular matrix. Pathology develops from 
an interplay between altered vasculature and immune-mediated inflammatory events.
85
 Genes 
associated with SSc are involved in TCR and cytokine receptor signalling (Table 1).
86
 A major 
feature of autoimmunity in SSc is high levels of autoantibodies to cellular proteins including 
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topoisomerase I enzyme (Scl-70).
85





IL-17 levels are elevated in the blood of SSc patients compared with healthy individuals.
88
 
Furthermore, several pro-inflammatory cytokines including IL-6 that promote Th17 cell 
differentiation are produced at high levels by immune cells including B cells.
89
 The indirect 
effects of IL-17 on fibrosis are likely to be mediated by the effect of IL-6 on fibroblast 
proliferation and increased production of pro-fibrotic factors. Thus, in experimental models of 
SSc, IL-17 stimulates fibroblast proliferation and increases key pro-fibrotic mediators such as 
TGFβ, connective tissue growth factor and collagen.
88,90
 Notably, the frequency of 
topoisomerase-reactive Th17 cells was reported to predict disease prognosis in SSc patients 
with interstitial lung disease.
91
 Interestingly, Th17 cells inhibit the ability of TGFβ to induce 




Similar to psoriasis, SSc patients have skin-resident Th17 cells. However, in contrast to 
psoriasis, in SSc patients these cells react with nuclear antigens rather than keratinocyte-
derived proteins. In addition, these Th17 cells are likely to promote autoantibody production by 
B cells at least in a subgroup of patients.
89






A number of factors are involved in changing Th17 cell responses from protective immunity to 
promoting inflammation and autoimmune diseases. The best link between Th17 homeostatic 
barrier functions and dysregulation leading to the failure of immunological tolerance, chronic 
inflammation and autoimmune disease mediation by Th17 cells is likely to result from 
responses to bacterial infections in the gut and, potentially, in the skin (Figure 1 and 2). Hence, 
an aberrant immune response to bacterial antigens leading to a propensity of self-antigen 
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presentation and Th17 cell responses in genetically susceptible individuals is a possible 
mechanism.
3,36,39,92
 The ability of Th17 cells to enhance B cell responses could be further 
evidence for a role for Th17 cells either directly, or through trans-differentiation to Tfh cells, in 




The lack of responsiveness to treatment with biologic anti-TNFα agents in some patients with 
RA and psoriasis is associated with the production of anti-nuclear antibodies and increased 
Th17 frequency and IL-17 production.
4,6
 In patients with SLE, altered expression of the 
ubiquitin editing enzyme TNFAIP3/A20 which functions down-stream of TNFR1 in the T 
cells/Th17 cells could be involved in promoting pathogenic Th17 cell responses (Table 1). 
Further studies are, however, required to determine how genetic polymorphisms contribute to 
Th17 cells expansion and their plasticity in chronic inflammatory autoimmune diseases. 
Further studies should also address the influence of patients’ microbiome and availability of 
self-antigens on mechanisms by which Th17 cells promote auto-antibody production. 
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Figure legends 
Figure 1. Role of Th17 cells in maintaining homeostasis. Th17 cells reside in 
mucosal membranes and in the skin. The gastrointestinal tract (GIT) microbiome, 
infections or a disrupted homeostasis can promote a surge in pro-inflammatory 
cytokine production, including high levels of IL-1β, IL-6 and IL-23. This induces 
resident T cells to differentiate to effector Th17 cells aided by antigen-presenting 
cells (APCs), such as dendritic cells (DCs). IL-17 and IL-22 production by these 
effector cells increases barrier functions, such as tighter junctions and the 
production of antimicrobial peptides. The production of IL-17 induces chemokine 
production and neutrophil recruitment. In the skin, C. albicans stimulates DCs and 
promotes IL-1β-dependent TRM IL-17 production, leading to antimicrobial protein 
and chemokine production and the recruitment of neutrophils. GIT tryptophan (Trp) 
and TGFβ promote Th17 cell trans-differentiation to IL-10-producing T cells.  M 
cells, that are part of Peyer’s patches, transport intestinal antigens from the gut 
lumen for presentation by DCs to the immune system leading to B cell activation. 
In this environment, Th17 cells transdifferentiate to Tfh cells that produce IL-21, 
which promote B cell development and IgA production. Tfh promotes plasma cell 
development.  
 
Figure 2. Th17 cells role in rheumatic diseases. Gut, left; Pathogenic (and certain 
commensal) bacterial species in the GIT can potentiate a Th17-mediated 
inflammatory responses. Self-antigens (red colour) can erroneously be presented by 
DCs to naïve T cells during GIT infections with pathogenic bacterial species 
resulting in autoreactive responses. In SLE, defective clearance of apoptotic cells 
leads to IL-23 production by DCs. IL-23 promotes Th17 cell differentiation and 
also facilitates Treg conversion to IL-17-producing cells. BAFF, which is also 
elevated in SLE, promotes further Th17 cell differentiation and B cell survival and 
proliferation leading to the production of autoantibodies with specificity for 
apoptotic cell debris. Skin, left; In the skin of patients with psoriasis, auto-antigens 
(red colour) are presented to TRM cells by APCs. These APC produce IL-23 leading 
to the differentiation of TRMs to Th17 cells. These cells, in turn, exacerbate skin 
pathology through the production of chemokines, neutrophil recruitment and the 
production of MMPs, and other mediators of inflammation. Synovium, right; In 
RA, Th17 cells augment synovial cartilage degradation and inflammation by 
This article is protected by copyright. All rights reserved. 
stimulation of synoviocytes leading to production of MMPs, IL-6. IL-17 can also 
induce RANK-L release from synoviocytes and osteoblasts thereby promoting 
osteoclastogenesis. Furthermore, IL-22 production by Th17 cells accelerates ectopic 
germinal centre formation and B cell proliferation and differentiation in inflamed 
synovia. IL-17 produced in these ectopic germinal centres enhances the production 
of pathogenic autoantibodies. 
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